There are 139 resources available
Q&A and discussion
Session: The role of surgery in specific situations
Resources:
Webcast
The new FIGO molecular classification in endometrial cancer
Presenter: Xavier Matias-guiu
Session: The evolving landscape in endometrial cancer: From staging to therapy
Resources:
Slides
Webcast
IO after IO: Exploring rechallenge strategies with monotherapies, IO/IO and TKI combinations
Presenter: Robert Coleman
Session: The evolving landscape in endometrial cancer: From staging to therapy
Resources:
Slides
Webcast
The role of endocrine therapy
Presenter: Jean Emmanuel Kurtz
Session: The evolving landscape in endometrial cancer: From staging to therapy
Resources:
Slides
Webcast
Q&A and discussion
Session: The evolving landscape in endometrial cancer: From staging to therapy
Resources:
Webcast
35MO - Quality-adjusted survival in patients with advanced or recurrent endometrial carcinoma treated with atezolizumab in combination with carboplatin-paclitaxel versus carboplatin-paclitaxel in the AtTEnd/ENGOT-EN7 trial
Presenter: Maria Pilar Barretina Ginesta
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
36MO - Patient-reported outcomes in primary advanced or recurrent endometrial carcinoma treated with atezolizumab or placebo in combination with carboplatin-paclitaxel in the AtTEnd/ENGOT-EN7 trial
Presenter: Yeh Chen Lee
Session: Mini Oral session 1
Resources:
Abstract
37MO - Dostarlimab plus chemotherapy in primary advanced or recurrent endometrial cancer (pA/rEC) in the RUBY trial: Overall survival (OS) by MMR status and molecular subgroups
Presenter: Robert Coleman
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
38MO - Progression-free survival (PFS) in primary advanced or recurrent endometrial cancer (pA/rEC) in the overall and mismatch repair proficient (MMR/MSS) populations and in histological and molecular subgroups: Results from part 2 of the RUBY trial
Presenter: Mansoor Raza Mirza
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
39MO - Phase III ENGOT-En9/LEAP-001 study: Lenvatinib + pembrolizumab (LEN/PEMBRO) vs chemotherapy (chemo) as first-line (1L) therapy for advanced or recurrent endometrial cancer
Presenter: Sandro Pignata
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast